Assessing Granulomatosis With Polyangiitis Activity: 18F-FDG PET/CT vs BVAS v3

Assessment of Disease Activity in Patients With Granulomatosis With Polyangiitis Using 18F-Fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography and Its Correlation With Birmingham Vasculitis Activity Score Version 3

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07712172

Enrollment

Registered

2026-07-17

Start date

2025-01-01

Completion date

2026-05-30

Last updated

2026-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Granulomatosis With Polyangiitis (Wegener's)

Keywords

GPA, Wegener's Granulomatosis, BVAS, Granulomatosis with polyangiitis, PET CT, 18F-FDG

Brief summary

The goal of this observational study is to quantify activity and extent of disease in patients with GPA using 18F-FDG PET/CT. The main questions it aims to answer are: Sensitivity of 18 F-FDG PET/CT in patients with GPA? Correlation of 18F-FDG PET/CT semi-quantitative parameters with BVAS v3?

Detailed description

Patients age more than 18 with active GPA were recruited and 18F-FDG PET/CT was done after clinical assessment and evaluation. BVAS v3 score was calculated and then patients underwent 18F-FDG PET/CT. Findings of the scans were evaluated by expert nuclear medicine physicians and various semiquantitative parameters were calculated. Sensitivity was then calculated and correlation of BVAS v3 score was done with the calculated semiquantitative parameters.

Interventions

DRUG18F-FDG

18 F-FDG PET/CT was done for patients with active GPA

DEVICE18F-FDG PET/CT

Use of 18F-FDG PET/CT scan in patients with active GPA

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with newly diagnosed or relapsed active GPA, Age more than or equal to18 years.

Exclusion criteria

Pregnant/ lactating women and non-consenting adults

Design outcomes

Primary

Measure	Time frame
Per-patient sensitivity of 18F-FDG PET/CT for detection of clinically active GPA and correlation of 18 F-FDG PET/CT semiquantitative parameters with BVAS v3	Baseline

Countries

India

Contacts

PRINCIPAL_INVESTIGATORDr Harmandeep Singh, MD

Postgraduate Institute of Medical Education and Research, Chandigarh, 160012

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 18, 2026